TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07224373: A Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults With Refractory Relapsing or Progre

Sponsor: AstraZeneca · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$316,608

Rescue Site Savings

+$211,072

Unlock Full NCT07224373 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07224373 Rescue Dossier →